and Clinical Oncology

Effects of glycogen synthase kinase inhibitor on glioblastoma multiforme cell line via apoptosis and cell signaling pathways

Camlar M.
Acikgoz E.
Demir K.
Uysal A.
Ozer F.
Selcuki M.
Aktug H.

January 2019

###EgeUn###AIM: To investigate the apoptotic and molecular effects of glycogen synthase kinase-3 (GS...

Effects of Glycogen Synthase Kinase-3β (GSK3β) Inhibition in Glioblastoma Using Novel Compounds

Rzepecka, Klaudia
Lawrence, Clare Louise
Moualla, Dima
Hayes, Joseph
Alder, Jane Elizabeth

October 2022

Abstract AIMS GSK3β is a constitutively conserved serine/threonine kinase involved in a number of bi...

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi, M.E.
Diserens, A.C.
Godard, S.
Dietrich, P.Y.
Regli, L.
Ostermann, S.
Otten, P.
Van Melle, G.
de Tribolet, N.
Stupp, R.

January 2004

PURPOSE: In the setting of a prospective clinical trial, we determined the predictive value of the m...

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling

ピコイリア
Pyko Ilya Vassilyevich

September 2013

13301甲第3924号博士（医学）金沢大学博士論文要旨Abstract 以下に掲載：Carcinogenesis. 34(10) pp.2206-2217 2013. Oxford Universi...

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling

ピコイリア
Pyko Ilya Vassilyevich

September 2013

13301甲第3924号博士（医学）金沢大学博士論文本文Full 以下に掲載：Carcinogenesis 34(10) pp.2206-2217 2013. Oxford University Pr...

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.

Gloria Perazzoli
Jose Prados
Raul Ortiz
Octavio Caba
Laura Cabeza
Maria Berdasco
Beatriz Gónzalez
Consolación Melguizo

The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. Howev...

Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure

Acikgoz, Eda
Guler, Gunnur
Camlar, Mahmut
Oktem, Gulperi
Aktug, Huseyin

January 2019

WOS: 000453111700019PubMed ID: 30388586Glioblastoma multiforme (GBM) is the most malignant and aggre...

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

Perazzoli, Gloria
Prados, Jose
Ortiz, Raul
Caba, Octavio
Cabeza, Laura
Berdasco, María
González Navarro, Beatriz
Melguizo, Consolación

Background: The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme pat...

Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.

Agnieszka Belter
Jakub Barciszewski
Anna-Maria Barciszewska

January 2020

Temozolomide (TMZ) is a drug of choice in glioblastoma treatment. Its therapeutic applications expan...

A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.

Anna-Maria Barciszewska
Dorota Gurda
Paweł Głodowicz
Stanisław Nowak
Mirosława Z Naskręt-Barciszewska

Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patien...

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

Gloria Perazzoli (811155)
Jose Prados (778445)
Raul Ortiz (778443)
Octavio Caba (811156)
Laura Cabeza (811157)
Maria Berdasco (5665351)
Beatriz Gónzalez (5665354)
Consolación Melguizo (5665357)

October 2015

<div><p>Background</p><p>The use of temozolomide (TMZ) has improved the prognosis for glioblastoma m...

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

Ciceroni, C.
Bonelli, M.
Mastrantoni, E.
Niccolini, C.
Laurenza, M.
Larocca, L. M. (ORCID:0000-0003-1739-4758)
Pallini, R. (ORCID:0000-0002-4611-8827)
Traficante, A.
Spinsanti, P.
Ricci-Vitiani, L.
Arcella, A.
De Maria Marchiano, R. (ORCID:0000-0003-2255-0583)
Nicoletti, F.
Battaglia, G.
Melchiorri, D.

January 2013

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSC...

Effects of Glycogen Synthase Kinase Inhibitor on Glioblastoma Multiforme Cell Line via Apoptosis and Cell Signaling Pathways

Çamlar, Mahmut
Açıkgöz, Eda
Demir, Kenan
Uysal, Ayşegül
Özer, Füsun
Selçuki, Mehmet
Aktuğ, Hüseyin

January 2019

AIM: To investigate the apoptotic and molecular effects of glycogen synthase kinase-3 (GSK-3) in gli...

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

CICERONI, CINZIA
BONELLI, MILTON
NICCOLINI, CRISTIANO
LAURENZA, MARTA
SPINSANTI, Paola
NICOLETTI, Ferdinando
BATTAGLIA, Giuseppe
MELCHIORRI, Daniela
E. Mastrantoni
L. M. Larocca
R. Pallini
A. Traficante
L. Ricci Vitiani
A. Arcella
R. De Maria

January 2013

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSC...

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

Ciceroni, C
Bonelli, M
Mastrantoni, E
Niccolini, C
Laurenza, M
Larocca, Lm (ORCID:0000-0003-1739-4758)
Pallini, R (ORCID:0000-0002-4611-8827)
Traficante, A
Spinsanti, P
Ricci-Vitiani, L
Arcella, A
De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)
Nicoletti, F
Battaglia, G
Melchiorri, D.

January 2013

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSC...

Effects of glycogen synthase kinase inhibitor on glioblastoma multiforme cell line via apoptosis and cell signaling pathways

Camlar M.
Acikgoz E.
Demir K.
Uysal A.
Ozer F.
Selcuki M.
Aktug H.

January 2019

###EgeUn###AIM: To investigate the apoptotic and molecular effects of glycogen synthase kinase-3 (GS...

Effects of Glycogen Synthase Kinase-3β (GSK3β) Inhibition in Glioblastoma Using Novel Compounds

Rzepecka, Klaudia
Lawrence, Clare Louise
Moualla, Dima
Hayes, Joseph
Alder, Jane Elizabeth

October 2022

Abstract AIMS GSK3β is a constitutively conserved serine/threonine kinase involved in a number of bi...

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi, M.E.
Diserens, A.C.
Godard, S.
Dietrich, P.Y.
Regli, L.
Ostermann, S.
Otten, P.
Van Melle, G.
de Tribolet, N.
Stupp, R.

January 2004

PURPOSE: In the setting of a prospective clinical trial, we determined the predictive value of the m...

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling

ピコイリア
Pyko Ilya Vassilyevich

September 2013

13301甲第3924号博士（医学）金沢大学博士論文要旨Abstract 以下に掲載：Carcinogenesis. 34(10) pp.2206-2217 2013. Oxford Universi...

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling

ピコイリア
Pyko Ilya Vassilyevich

September 2013

13301甲第3924号博士（医学）金沢大学博士論文本文Full 以下に掲載：Carcinogenesis 34(10) pp.2206-2217 2013. Oxford University Pr...

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.

Gloria Perazzoli
Jose Prados
Raul Ortiz
Octavio Caba
Laura Cabeza
Maria Berdasco
Beatriz Gónzalez
Consolación Melguizo

The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. Howev...

Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure

Acikgoz, Eda
Guler, Gunnur
Camlar, Mahmut
Oktem, Gulperi
Aktug, Huseyin

January 2019

WOS: 000453111700019PubMed ID: 30388586Glioblastoma multiforme (GBM) is the most malignant and aggre...

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

Perazzoli, Gloria
Prados, Jose
Ortiz, Raul
Caba, Octavio
Cabeza, Laura
Berdasco, María
González Navarro, Beatriz
Melguizo, Consolación

Background: The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme pat...

Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.

Agnieszka Belter
Jakub Barciszewski
Anna-Maria Barciszewska

January 2020

Temozolomide (TMZ) is a drug of choice in glioblastoma treatment. Its therapeutic applications expan...

A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.

Anna-Maria Barciszewska
Dorota Gurda
Paweł Głodowicz
Stanisław Nowak
Mirosława Z Naskręt-Barciszewska

Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patien...

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

Gloria Perazzoli (811155)
Jose Prados (778445)
Raul Ortiz (778443)
Octavio Caba (811156)
Laura Cabeza (811157)
Maria Berdasco (5665351)
Beatriz Gónzalez (5665354)
Consolación Melguizo (5665357)

October 2015

<div><p>Background</p><p>The use of temozolomide (TMZ) has improved the prognosis for glioblastoma m...

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

Ciceroni, C.
Bonelli, M.
Mastrantoni, E.
Niccolini, C.
Laurenza, M.
Larocca, L. M. (ORCID:0000-0003-1739-4758)
Pallini, R. (ORCID:0000-0002-4611-8827)
Traficante, A.
Spinsanti, P.
Ricci-Vitiani, L.
Arcella, A.
De Maria Marchiano, R. (ORCID:0000-0003-2255-0583)
Nicoletti, F.
Battaglia, G.
Melchiorri, D.

January 2013

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSC...

Effects of Glycogen Synthase Kinase Inhibitor on Glioblastoma Multiforme Cell Line via Apoptosis and Cell Signaling Pathways

Çamlar, Mahmut
Açıkgöz, Eda
Demir, Kenan
Uysal, Ayşegül
Özer, Füsun
Selçuki, Mehmet
Aktuğ, Hüseyin

January 2019

AIM: To investigate the apoptotic and molecular effects of glycogen synthase kinase-3 (GSK-3) in gli...

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

CICERONI, CINZIA
BONELLI, MILTON
NICCOLINI, CRISTIANO
LAURENZA, MARTA
SPINSANTI, Paola
NICOLETTI, Ferdinando
BATTAGLIA, Giuseppe
MELCHIORRI, Daniela
E. Mastrantoni
L. M. Larocca
R. Pallini
A. Traficante
L. Ricci Vitiani
A. Arcella
R. De Maria

January 2013

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSC...

Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas

Ciceroni, C
Bonelli, M
Mastrantoni, E
Niccolini, C
Laurenza, M
Larocca, Lm (ORCID:0000-0003-1739-4758)
Pallini, R (ORCID:0000-0002-4611-8827)
Traficante, A
Spinsanti, P
Ricci-Vitiani, L
Arcella, A
De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)
Nicoletti, F
Battaglia, G
Melchiorri, D.

January 2013

Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSC...

Effects of glycogen synthase kinase inhibitor on glioblastoma multiforme cell line via apoptosis and cell signaling pathways

Camlar M.
Acikgoz E.
Demir K.
Uysal A.
Ozer F.
Selcuki M.
Aktug H.

January 2019

###EgeUn###AIM: To investigate the apoptotic and molecular effects of glycogen synthase kinase-3 (GS...

Effects of Glycogen Synthase Kinase-3β (GSK3β) Inhibition in Glioblastoma Using Novel Compounds

Rzepecka, Klaudia
Lawrence, Clare Louise
Moualla, Dima
Hayes, Joseph
Alder, Jane Elizabeth

October 2022

Abstract AIMS GSK3β is a constitutively conserved serine/threonine kinase involved in a number of bi...

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi, M.E.
Diserens, A.C.
Godard, S.
Dietrich, P.Y.
Regli, L.
Ostermann, S.
Otten, P.
Van Melle, G.
de Tribolet, N.
Stupp, R.

January 2004

PURPOSE: In the setting of a prospective clinical trial, we determined the predictive value of the m...

and Clinical Oncology

Abstract

Extracted data

and Clinical Oncology

Abstract

Extracted data

Related items

Related items